There was a dose-response relationship between increasing mg/kg dose and the maximum decrease in systolic (ρ = 0.463; Spearman's, p = 0.02) and diastolic blood pressure (r = 0.42; Pearson's, p = 0.02), and with the maximum increment in blood potassium (r = 0.70, p<0.001) and maximum decrement in bicarbonate concentrations (r = 0.53, p = 0.003) and pH (r = 0.48, p = 0.007).
The correlation between plasma pazopanib concentrations and the maximum decrease in sVEGFR2 was weak using the linear model (r=0.27).
The maximum decrease did not deviate significantly between the groups, u-AQP2 (Group 1: - 27%, Group 2: - 33%, Group 3: - 32%, and Group 4: - 19%).
The relationship between the topotecan exposure and the decrease in THR indicated that the maximum decrease is not likely to be reached with the doses studied.
There was an association between the maximum CA 19-9 decreand and pain and physical well-being, respectively, but the maximum decrease was not prognostic for these domains: These group differences in pain and physical well-being were present already before the maximum decrease.
Finally, the maximum decrease in pressure over time during diastole (dP/dt min) showed a significant interaction between group and time (p < 0.01) (data not shown).
The mid point of the fluorescence change between maximum decrease and that with no peptide for Ala-Ala-Ala is ∼125 µM and 10 µM for Ala Ala, an approximate 10-fold difference.
The amount of motion that occurs at the SCO was defined as the difference between the maximum increase and maximum decrease in the distance between measuring points; determined for each cycle and per measuring point.
The distance between the sharp maxima decreases for the smaller n, and for the ground state they merge together forming one symmetric peak with its magnitude being the largest as compared to the excited levels.
The use of a finite element model showed that no correlation existed between the maximum shear strain and the decrease of the ADC.
